Rifamycin B

Rifamycin B (4-O- (Carboxymethyl) -Rifamycin) is a member of ansamycin antibiotics family with an anti-mycobacterial activity against tuberculosis, leprosy and AIDS-related mycobacterial infections. Rifamycin B is a metabolic product of Nocardia inediterranei, which can yield Rifamycin O and Rifamycin S (HY-125365) by microbial transformation[1][2].

Product Specifications

CAS Number

[13929-35-6]

Product Name Alternative

4-O- (Carboxymethyl) -Rifamycin

UNSPSC

12352005

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/rifamycin-b.html

Purity

95.0

Smiles

C/C(C(N1)=O)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]([C@@H](OC)/C=C/O[C@]2(C)C(C3=C(O2)C(C)=C(O)C4=C3C(OCC(O)=O)=CC1=C4O)=O)C

Molecular Formula

C39H49NO14

Molecular Weight

755.80

References & Citations

[1]Seong BL, et al. Microbial transformation of rifamycin B: a new synthetic approach to rifamycin derivatives. J Antibiot (Tokyo) . 1983 Oct;36 (10) :1402-4.|[2]Jin ZH, et al. Scale-up of rifamycin B fermentation with Amycolatoposis mediterranei. J Zhejiang Univ Sci. 2004 Dec;5 (12) :1590-6.